Timothy L. Chen

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation

Alexandru D. Buhimschi, Haley A. Armstrong, Momar Toure et al. · Biochemistry · 2018 · 372 citations

Medicine, Medicinal Chemistry, Oncology +13

Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease

Erin Hertlein, Kyle A. Beckwith, Gerard Lozanski et al. · PLoS ONE · 2013 · 64 citations · Full text

Life Sciences, Cell Biology, Oncology +15

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells

Sneha Gupta, Erin Hertlein, Yanhui Lu et al. · Clinical Cancer Research · 2013 · 38 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML

Joshua F. Zeidner, Tara L. Lin, Rina Li Welkie et al. · Journal of Clinical Oncology · 2025 · 30 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

Cecelia Miller, Amy S. Ruppert, Sydney Fobare et al. · Oncotarget · 2017 · 28 citations · Full text

Medicine, Molecular Biology, Oncology +13